Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
  • Articles
  • Law Firms
  • Law Firms
  • Organizations
  • Organizations
    • HEALTH CARE REFORM—D.D.C.: QHP certification denial not arbitrary and capricious where applicant demonstrated pattern of missteps
    • ADMINISTRATION OF FDC ACT—D. Md.: Attempt to require FDA to skip premarket efficacy studies for Alzheimer’s drugs dismissed
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: DAB upholds penalties against Texas nursing facility
    • ANTITRUST—SETTLEMENT AGREEMENTS: Teva to pay combined $450 million to settle federal price-fixing, kickback allegations
    • GENERAL HEALTH CARE NEWS—D. Md.: Court denies vacatur of $26 million default judgment on allegations of COVID-19 testing fraud
    • HEALTH CARE COMPLIANCE NEWS—20 states file suit against federal nursing home staffing rule
    • HEALTH INFORMATION TECHNOLOGY—E.D. Pa.: Court upholds LabCorp's arbitration clause in class action over data sharing with Google
    • LABELING AND PACKAGING (FOOD, DRUGS & MEDICAL DEVICES)—S.D. Cal.: ‘All Natural’ false labeling suit against Snapple can proceed
    • MEDICAL DEVICES—FDA GUIDANCE NOTICES: FDA issues guidance on dental implants
    • PRESCRIPTION DRUGS—OTHER AGENCY DOCUMENTS: CMS seeks stakeholder input on innovative Medicare $2 Drug List Model to boost prescription affordability
    • REGULATION TRACKER—Information on pending or recently adopted regulations and regulation amendments
  • Articles
  • Articles
  • Law Firms
  • Law Firms
  • Organizations
  • Organizations

    Health Law Daily Wrap Up, MEDICAL DEVICES—FDA GUIDANCE NOTICES: FDA issues guidance on dental implants, (Oct 15, 2024)

    By WK Editorial Staff

    The FDA announced the availability of a final guidance entitled “Endosseous Dental Implants and Endosseous Dental Implant Abutments—Performance Criteria for Safety and Performance Based Pathway.”

    The device-specific guidance ident ...

    By WK Editorial Staff

    The FDA announced the availability of a final guidance entitled “Endosseous Dental Implants and Endosseous Dental Implant Abutments—Performance Criteria for Safety and Performance Based Pathway.”

    The device-specific guidance identified in the notice was developed in accordance with the finalized guidance entitled “Safety and Performance Based Pathway.” This guidance has been implemented without prior comment, but it remains subject to comment in accordance with the FDA’s good guidance practices (Notice, 89 Fed. Reg. 83019 (Oct. 15, 2024)).

    Dates. The announcement of the guidance was published in the Federal Register on October 15, 2024.

    FederalRegisterIssuances: FDAGuidanceNotices FDCActNews MDeviceNews SafetyNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use